Eradivir Secures $10.25 Million for Flu Treatment Development
Eradivir, a biotech company in the preclinical stage that focuses on antiviral treatments, has successfully completed a Series A funding round, raising $10.25 million. This funding is intended to support their Phase 2a challenge study of the EV25 treatment for influenza. As CEO Martin Low explained, the EV25 treatment has shown strong results in preclinical models when compared to current influenza therapies.
EV25 Shows Strong Potential
Martin Low pointed out that within just 24 hours of administration, EV25 was able to reduce live virus levels to undetectable numbers during preclinical studies. The upcoming Phase 2a and Phase 2b trials are designed to further evaluate EV25's safety and effectiveness in human subjects, helping to move from initial proof of concept toward practical applications.
Funding Details and Aspirations
This funding achievement was particularly noteworthy due to the unique profile of its investors. Contributions came not only from Philip Low, board members, and internal supporters but also from small institutions, friends, and family. Martin Low expressed confidence that the interests of these investors align closely with the larger goals of Purdue University and Philip Low's initiatives.
Previous Funding Successes
Before this success, Eradivir already secured $10.8 million from earlier funding rounds and an additional $1 million from the National Science Foundation, along with support from the Biomedical Advanced Research and Development Authority’s Innovation Division. The company now aims to raise an extra $10 million to fund three essential trials, which will encompass the Phase 1 single and multiple ascending dose study, along with the Phase 2a and Phase 2b human studies.
Strategic Funding and Partnerships
Martin Low noted that the objective is to acquire these remaining funds through non-dilutive means. This means they will seek resources from BARDA, the Department of Defense, and the National Institutes of Health. This careful strategy enables the company to advance its trials without diluting shareholder equity.
Eradivir's Mission and Methodology
At its core, Eradivir is focused on leveraging the immune system for therapeutic purposes. By employing advanced small-molecule, bispecific immunotherapy, the company is better able to target diseased cells and enhance the immune response for quicker recovery. The innovative EV25 drug is their first step into human clinical trials, targeting influenza directly.
Purdue University's Key Role
In collaboration with Purdue University, Eradivir is associated with the Purdue Innovates Office of Technology Commercialization. This office plays an important role in promoting innovation and advancing the university’s research initiatives by managing and protecting its intellectual property. Over the last fiscal year, this office has supported many deals and technology transfers that boost Purdue’s research capabilities.
Looking Ahead for Eradivir
Purdue University, with its enrollment of over 105,000 students in a variety of programs, is recognized for its excellence in research. The institution is dedicated to affordability and innovation, creating an environment that promotes scientific and technological advancements. As Eradivir moves forward into advanced clinical trials, its work could not only impact influenza treatments but also expand possibilities for antiviral therapies.
Frequently Asked Questions
What is Eradivir focusing on with its recent funding?
Eradivir is utilizing the $10.25 million funding to advance clinical trials for its EV25 influenza therapeutic.
How effective is EV25 in preliminary studies?
Preclinical studies indicate that EV25 can reduce the amount of live influenza virus to undetectable levels within 24 hours of administration.
What collaborations does Eradivir have with Purdue University?
Eradivir collaborates with the Purdue Innovates Office of Technology Commercialization to leverage Purdue's research initiatives and intellectual property.
What trials is Eradivir planning to conduct next?
Eradivir plans to conduct Phase 2a and Phase 2b trials to assess EV25's safety and efficacy in human patients.
What is the long-term goal for Eradivir's funding strategy?
Eradivir aims to raise additional funds through non-dilutive sources like BARDA and the Department of Defense to support its clinical trial goals.
